Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263891 | 0.86 | — | — | |
| SCHEMBL22420083 | 0.83 | MMP1 (0.31) | METAP2METAP1 | |
| SCHEMBL12313010 | 0.83 | METAP2 (0.37) | METAP2METAP1 | |
| SCHEMBL15948443 | 0.72 | PKM (0.31) | — | |
| SCHEMBL12263888 | 0.69 | MME (0.33) | — | |
| SCHEMBL12656921 | 0.68 | CTSS (0.32) | — | |
| SCHEMBL12040106 | 0.68 | CA1 (0.41) | — | |
| SCHEMBL12040036 | 0.68 | CA1 (0.41) | — | |
| SCHEMBL18431681 | 0.66 | METAP2 (0.33) | METAP2METAP1 | |
| SCHEMBL10093672 | 0.65 | GAA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | METAP2 2174/4885METAP1 2346/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | METAP2 2670/4885METAP1 2075/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | METAP2 1615/4885METAP1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.